Literature DB >> 17362567

Breast cancer screening--prevalence of disease in women who only respond after an invitation reminder.

Solveig Hofvind1.   

Abstract

An analysis of the Norwegian Breast Cancer Screening Programme, including 1,390,310 screening examinations, showed an attendance rate of 71.7% in response to one invitation letter (ordinary attendees) and a further 4.5% increase only after an additional reminder (reminded attendees). Our aim was to examine the prevalence of breast cancer in ordinary and reminded attendees, the frequency of positive mammograms, and the positive predictive value in the two groups. The prevalence of breast cancer in ordinary attendees was 5.6 per 1000 screens compared with 6.3 per 1000 screens in reminded attendees (p<0.001). The frequencies of positive mammograms were 3.5% and 4.0% (p<0.001), and the positive predictive values were 15.9% and 15.2% (p=0.387), respectively, in ordinary and reminded attendees. The risk of breast cancer is higher in women who respond only after a reminder letter, indicating that the value of sending a reminder should be assessed in the light of these results, as well as by the increase in the attendance rate.

Entities:  

Mesh:

Year:  2007        PMID: 17362567     DOI: 10.1258/096914107780154503

Source DB:  PubMed          Journal:  J Med Screen        ISSN: 0969-1413            Impact factor:   2.136


  3 in total

1.  Using the European guidelines to evaluate the Norwegian Breast Cancer Screening Program.

Authors:  Solveig Hofvind; Berta Geller; Pamela M Vacek; Steinar Thoresen; Per Skaane
Journal:  Eur J Epidemiol       Date:  2007-06-27       Impact factor: 8.082

2.  Physical activity and mammographic density in a cohort of postmenopausal Norwegian women; a cross-sectional study.

Authors:  Samera Azeem Qureshi; Merete Ellingjord-Dale; Solveig Hofvind; Anna H Wu; Giske Ursin
Journal:  Springerplus       Date:  2012-12-21

3.  Breast cancer mortality in participants of the Norwegian Breast Cancer Screening Program.

Authors:  Solveig Hofvind; Giske Ursin; Steinar Tretli; Sofie Sebuødegård; Bjørn Møller
Journal:  Cancer       Date:  2013-05-29       Impact factor: 6.860

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.